相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease
Laust Dupont Rasmussen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
PCSK9 Involvement in Aortic Valve Calcification
Paolo Poggio et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Lipid management in patients with chronic kidney disease
Charles J. Ferro et al.
NATURE REVIEWS NEPHROLOGY (2018)
Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism
Marion Morena et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes
Luca Liberale et al.
CURRENT MEDICINAL CHEMISTRY (2017)
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
Zhi-Han Tang et al.
ATHEROSCLEROSIS (2017)
PCSK9 regulates the chemokine receptor CCR2 on monocytes
Jana Grune et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia
Rodrigo Alonso et al.
ATHEROSCLEROSIS (2016)
A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification
Claudia Goettsch et al.
ATHEROSCLEROSIS (2016)
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors
Karin Leander et al.
CIRCULATION (2016)
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Brian A. Ference et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
DIFFERENTIAL EXPRESSION OF PCSK9 MODULATES INFECTION, INFLAMMATION, AND COAGULATION IN A MURINE MODEL OF SEPSIS
Dhruva J. Dwivedi et al.
SHOCK (2016)
Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk
Montse Guardiola et al.
CLINICAL SCIENCE (2015)
Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials
A. Sahebkar et al.
DIABETES OBESITY & METABOLISM (2015)
Cause of Death in Patients with Reduced Kidney Function
Stephanie Thompson et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: Multicenter prospective study in Italy
Luca De Nicola et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2015)
Plasma PCSK9 in Nephrotic Syndrome and in Peritoneal Dialysis: A Cross-sectional Study
Kyubok Jin et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
Elevated Circulating PCSK-9 Concentration in Renal Failure Patients is Corrected by Renal Replacement Therapy
Marcin Konarzewski et al.
AMERICAN JOURNAL OF NEPHROLOGY (2014)
Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels
H. Abujrad et al.
ATHEROSCLEROSIS (2014)
KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient
Christoph Wanner et al.
KIDNEY INTERNATIONAL (2014)
Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor: Evidence for a Reciprocal Regulation
Hagai Tavori et al.
CIRCULATION (2013)
Association between LDL-C and Risk of Myocardial Infarction in CKD
Marcello Tonelli et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Bengt C. Fellstroem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment
Gilles Lambert et al.
CLINICAL CHEMISTRY (2008)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
C Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients
AK Cheung et al.
KIDNEY INTERNATIONAL (2000)
分享论文
